Erasca, Tango Therapeutics enter clinical collaboration, supply agreement

Erasca (ERAS) announced a clinical trial collaboration and supply agreement, CTCSA, with Tango Therapeutics (TNGX) to evaluate Erasca’s pan-RAS molecular glue, ERAS-0015, with Tango’s PRMT5 inhibitor, vopimetostat. This agreement will support a Phase 1/2 clinical trial evaluating ERAS-0015 in combination with vopimetostat in patients with MTAPdel pancreatic or MTAPdel RASm non-small cell lung cancer. Erasca will supply ERAS-0015 free of charge, and Tango will be the trial sponsor. Each company will retain commercial rights to their respective compound, and the agreement is mutually non-exclusive.